RGNX REGENXBIO Inc.

19.90
+0  (0%)
Previous Close 19.90
Open 19.75
Price To book 2.92
Market Cap 526.85M
Shares 26,475,000
Volume 82,109
Short Ratio 6.04
Av. Daily Volume 214,898

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 enrollment to be initiated 1H 2017.
RGX-501
Homozygous familial hypercholesterolemia (HoFH)
Phase 1/2 enrollment to be initiated 2H 2017.
RGX-111
Mucopolysaccharidosis Type I (MPS I)

Latest News

  1. D.C.-area biotech stocks fall on Trump's tough talk on industry
  2. REGENXBIO Provides Year-End 2016 Corporate Update
  3. REGENXBIO INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements
  4. REGENXBIO Provides Year-End 2016 Corporate Update
  5. REGENXBIO, Inc. – Value Analysis (NASDAQ:RGNX) : December 23, 2016
  6. REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : December 22, 2016
  7. Hedge Funds Have This To Say About Peapack-Gladstone Financial Corp (PGC)
  8. Hedge Funds Are Betting On Regenxbio Inc (RGNX)
  9. Voyager Therapeutics and REGENXBIO Announce Exercise of Options for Rights to NAV Vectors
  10. REGENXBIO and Voyager Therapeutics Announce Exercise of Options for Rights to NAV Vectors
  11. ETFs with exposure to REGENXBIO, Inc. : November 23, 2016
  12. REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016
  13. REGENXBIO to Present at the 28th Annual Piper Jaffray Healthcare Conference
  14. REGENXBIO INC. Financials
  15. Regenxbio Inc Earnings Call scheduled for 4:30 pm ET today
  16. REGENXBIO Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
  17. REGENXBIO INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  18. REGENXBIO Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
  19. Q3 2016 Regenxbio Inc Earnings Release - Before Market Open
  20. REGENXBIO to Host Conference Call on November 9 to Discuss Third Quarter 2016 Financial Results and Recent Operational Highlights

SEC Filings

  1. EFFECT - Notice of Effectiveness 17515636
  2. 8-K - Current report 17512978
  3. S-3/A [Amend] - Registration statement under Securities Act of 1933 162075367
  4. CT ORDER - Confidential treatment order 162070301
  5. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 162069215
  6. S-3 - Registration statement under Securities Act of 1933 162056968
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161984514
  8. 8-K - Current report 161984324
  9. 8-K - Current report 161881251
  10. 8-K - Current report 161834794